Anti-CTLA-4 Monoclonal Antibody SHR-8068 clinical trials
Also written SHR-8068.
Its developmentBy Jiangsu HengRui Medicine, step by step16 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-CTLA-4 Monoclonal Antibody SHR-8068 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-CTLA-4 Monoclonal Antibody SHR-8068 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2026 (8)
| Year | Studies |
|---|---|
| 2024 | 6 |
| 2025 | 3 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 4
Suzhou Suncadia Biopharmaceuticals Co., Ltd. (10) · The Affiliated Hospital of Qingdao University (1) · Fudan University (1) · Shanghai Zhongshan Hospital (1) · West China Hospital (1) · Shanghai Shengdi Pharmaceutical Co., Ltd (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Shanghai Hengrui Pharmaceutical Co., Ltd. (1)
Often tested with
Tested in the same studies.
Adebrelimab (7) · HRS-7058 (2) · Oxaliplatin (1) · Capecitabine (1) · Paclitaxel (1) · Cisplatin (1) · SHR-1826 (1) · SHR-1701 (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test Anti-CTLA-4 Monoclonal Antibody SHR-8068.
- Nov 2026SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal CancerPhase 1/2 · West China Hospital
- Jul 2027A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular CarcinomaPhase 2 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Nov 2027A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung CancerPhase 2 · Jiangsu HengRui Medicine Co., Ltd.
Studies
Open first, then newest update. How each study uses Anti-CTLA-4 Monoclonal Antibody SHR-8068 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular CarcinomaNot yet recruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07691762Written as SHR-8068 + Adebrelimab + Bevacizumab
- A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)RecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06618664Written as SHR-8068
- Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell CarcinomRecruitingPhase 1/2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07239596Written as SHR-8068 ; SHR-4610
- The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung CancerNot yet recruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07704645Written as Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection
- A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular CarcinomaNot yet recruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07682272Written as SHR-8068 Injection
- A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal CancerRecruitingPhase 2/3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07454720Written as Adebrelimab in combination with SHR-8068 and chemotherapy
- A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung CancerRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07241767Written as FH-006; SHR-1316 ; SHR-8068
- Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal CancerNot yet recruitingPhase 2Fudan UniversityNCT07503639Written as SHR-8068
- A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)RecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07229625Written as SHR-8068 Injection
- Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma:A Randomized, Non-comparative Phase 2 StudyNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07266025Written as SHR-8068
- A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ CancerRecruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07110571Written as SHR-8068 Injection
- A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingPhase 1/2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06589778Written as SHR-8068
- SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal CancerNot yet recruitingPhase 1/2West China HospitalNCT06373133Written as SHR-8068
- A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC PatientsNot yet recruitingPhase 2/3Shanghai Shengdi Pharmaceutical Co., LtdNCT06335355Written as Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin
- Comparative Pharmacokinetics of SHR-8068 and Ipilimumab in Healthy Chinese MenCompletedPhase 1The Affiliated Hospital of Qingdao UniversityNCT07852325Written as SHR-8068
- A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal CancerActive, not recruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07071714Written as SHR-8068 Injection
- Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal CancerActive, not recruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06247956Written as SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection
Given beside what is tested · 8 — Anti-CTLA-4 Monoclonal Antibody SHR-8068 is usual care or a partner of the new treatment
- Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal AdenocarcinomaRecruitingPhase 1/2Fudan UniversityNCT06427239Written as SHR-8068
- A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid TumorsRecruitingPhase 1/2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06703177Written as SHR-8068
- SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical CancerRecruitingPhase 1/2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06859775Written as SHR-8068
- A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLCRecruitingPhase 1/2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06754930Written as SHR-8068
- A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract CancerRecruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06778031Written as SHR-8068
- A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial CarcinomaRecruitingPhase 1/2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06639347Written as SHR-8068 injection
- Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular CarcinomaRecruitingPhase 1/2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT05444088Written as SHR-8068
- SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract CancerActive, not recruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06465563Written as SHR-8068